Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications

Abstract

As a result of cross-species transmission in December 2019, the coronavirus disease 2019 (COVID-19) became a serious endangerment to human health and the causal agent of a global pandemic. Although the number of infected people has decreased due to effective management, novel methods to treat critical COVID-19 patients are still urgently required. This review describes the origins, pathogenesis, and clinical features of COVID-19 and the potential uses of mesenchymal stem cells (MSCs) in therapeutic treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients. MSCs have previously been shown to have positive effects in the treatment of lung diseases, such as acute lung injury, idiopathic pulmonary fibrosis, acute respiratory distress syndrome, lung cancer, asthma, and chronic obstructive pulmonary disease. MSC mechanisms of action involve differentiation potentials, immune regulation, secretion of anti-inflammatory factors, migration and homing, anti-apoptotic properties, antiviral effects, and extracellular vesicles. Currently, 74 clinical trials are investigating the use of MSCs (predominately from the umbilical cord, bone marrow, and adipose tissue) to treat COVID-19. Although most of these trials are still in their early stages, the preliminary data are promising. However, long-term safety evaluations are still lacking, and large-scale and controlled trials are required for more conclusive judgments regarding MSC-based therapies. The main challenges and prospective directions for the use of MSCs in clinical applications are discussed herein. In summary, while the clinical use of MSCs to treat COVID-19 is still in the preliminary stages of investigation, promising results indicate that they could potentially be utilized in future treatments.

Introduction

In December 2019, there was a global outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), known as the coronavirus disease 2019 (COVID-19) [1, 2]. Cross-species transmissions lead to the outbreak, which was found to seriously endanger human health [3, 4]. The main routes of transmission were identified as respiratory droplets, direct contact, fecal–oral, mother-to-child, and aerosols [5, 6]. On March 11, 2020, the WHO issued an early warning of the global spread of COVID-19 and increased the impact level from epidemic to “global pandemic” [7]. As of November 17, 2021, over 253, 640, 000 cases of COVID-19 infection and 5, 104, 899 subsequent deaths were confirmed worldwide (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Due to the suddenness of the outbreak, there were no effective antiviral drugs available to immediately eliminate COVID-19. Furthermore, to date, effective control using drugs has not yet been achieved and is thus still in development. Although the spread rate of SARS-CoV-2 infections was initially controlled, new cases and mortality rates are still increasing globally. Of the reported COVID-19 cases globally, 13.8% were classified as severe, 6.1% were critical, and 2.3% were fatal [8, 9]. Therefore, the development of effective treatments for COVID-19 remains imperative.

Of the great efforts made worldwide to control COVID-19 [10, 11], vaccine research has clearly been important in controlling infection rates [12–17]. Initially, Zhu et al. [18] and Folegati et al. [19] reported that in human clinical trials the COVID-19 vaccine had acceptable safety, tolerance, immunogenicity, and efficacy. Many other organizations then quickly developed effective vaccines, such as the BNT162 mRNA vaccine sponsored by Pfizer Inc. and BioNTech SE [20–22], the adenovirus ChAdOx1 nCoV-19 (AZD1222) vaccine sponsored by AstraZeneca in the United Kingdom [23, 24], the mRNA-1273 vaccine co-sponsored by Moderna, Inc. and the National Institute of Allergy and Infectious Diseases of the United States of America [25, 26], the recombinant NVX-CoV2373 vaccine developed by Novavax, Inc. in the United States of America [27, 28], the recombinant Sputnik V vaccine co-sponsored by Gamaleya Research Institute of Epidemiology and Microbiology and the Health Ministry of the Russian Federation of Russia [29], the recombinant adenovirus type-5 (Ad5) vectored vaccine co-developed by the CanSino Biologics Inc. and Beijing Institute of Biotechnology of China [18, 30], the inactivated vaccine (BBIBP-CorV) sponsored by the Beijing Institute of Biological Products Company Limited of China [31, 32], the inactivated vaccine (CoronaVac) sponsored by Beijing Sinovac Life Sciences of China [33, 34], and the inactivated vaccine (BBV152) sponsored by Bharat Biotech International Limited, the Indian Council of Medical Research, and the National Institute of Virology of India [35, 36]. Clinical research results found that these vaccines were safe and effective [21, 22, 26, 28–30, 36], and some were mass produced for practical application. To date, billions of people have now been vaccinated for COVID-19, and the data continue to show that they are safe without serious negative side effects [37, 38]. All approved COVID-19 vaccines will continue to be monitored for long-term safety. Furthermore, some drugs (such as remdesivir, favipiravir, and dexamethasone) have also shown positive preliminary results in randomized, controlled, open-label clinical trials [39–41]. However, there are currently no specific drugs for the treatment of COVID-19, and consequently, novel methods to treat SARS-CoV-2 are urgently required.

Mesenchymal stem cells (MSCs) have the capacity to self-renew and differentiate, and MSC-based therapies have received much attention in both basic medicine and clinical research [42–45]. MSCs can be acquired from most human tissues, including but not limited to, bone marrow (BM), adipose tissue (AD), umbilical cord (UC), Wharton’s jelly (WJ), peripheral blood, menstrual blood, placenta, endometrium, amniotic membrane, amniotic fluid, fetal, dental pulp, urine, liver, lung, spleen, intestine, muscle, and synovium [46–50]. MSC-based therapies mainly rely on their self-renewal ability, pluripotent differentiation, low immunogenicity, anti-inflammatory function, and a homing ability to damaged tissues [51–55]. Importantly, MSCs have a unique immuno-regulation mechanism for mediating innate and adaptive immune responses [56, 57]. An increasing number of clinical studies have shown great promise in various diseases through the transplantation of MSCs [42, 58–60]. Wilson et al. used allogeneic MSCs in patients with acute respiratory distress syndrome (ARDS) and found no adverse reactions, such as hypoxemia, arrhythmia, and ventricular tachycardia, and also showed good therapeutic effects [61]. Our group reported that menstrual blood-derived MSC implantation significantly reduced the mortality of ARDS patients induced by the influenza A (H7N9) pandemic [62]. Angiotensin-converting enzyme 2 (ACE2) has been verified as a receptor by which SARS-CoV-2 enters target cells [63, 64]. Interestingly, researchers have shown that MSCs do not express ACE2 and are resistant to SARS-CoV-2 infection [65, 66]. Therefore, MSC-based treatments may be promising for patients with COVID-19, especially those in which the disease is classified as severe or critical.

This review focuses on the potential mechanisms of MSCs and clinical studies using MSC transplantation for the treatment of COVID-19. The aim is to improve understanding of the current MSC-based treatments for COVID-19 and provide guidance for their further applications in clinical medicine.

Epidemiology of COVID-19

Origins of SARS‑CoV‑2

Since the beginning of the twenty-first century, three coronaviruses have crossed the species barrier and been transmitted from animals to humans. These viruses include severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 [67, 68], all of which can cause fatal lung damage. Human-to-human transmission of SARS-CoV, MERS-CoV, and SARS-CoV-2 mainly occurs through respiratory droplets when an infected person coughs/sneezes/talks [69]. The newly discovered coronavirus, SARS-CoV-2, is an encapsulated, positive sense, single-stranded RNA virus that causes global fulminant infections [70, 71]. SARS-CoV-2 is in the Sarbecovirus subgenus of the β-coronavirus genus. According to genome comparisons, the similarity between SARS-CoV and SARS-CoV-2 at the nucleotide level is approximately 79% [72]. SARS-CoV and MERS-CoV viruses are thought to originate from bats, while civet cats and dromedaries are intermediate hosts of SARS-CoV and MERS-CoV, respectively, which cause zoonotic transmission [73, 74]. Preliminary epidemiological investigations have shown that the source infection for SARS-CoV-2 can be traced back to a live seafood wild animal market [75]. Genome sequence analysis showed that SARS-CoV-2 was very similar to a bat coronavirus (approximately 96% identical), and it is considered that SARS-CoV-2 may have been transmitted to humans through bats [72, 76, 77]. Interestingly, Lam et al. found several speculative pangolin coronavirus sequences that were 85.5–92.4% similar to SARS-CoV-2 [78]. Additional studies have shown that there are a variety of Malayan pangolin (Manis javanica) coronavirus lineages similar to SARS-CoV-2 genes, further supporting the hypothesis that pangolins are potential intermediate hosts [78, 79]. Recently, researchers discovered that minks, cats, and dogs are also sensitive to SARS-CoV-2 [80–82], but whether they are intermediate hosts requires further investigation. While bats and pangolins are currently considered to be the intermediate hosts of SARS-CoV-2 (Fig. 1a), further investigation is required to identify the exact source and other intermediate hosts.

Fig. 1.

Basic characteristics and entry of SARS-CoV-2 into the host pneumocyte. a Bats and pangolins are thought to be two of the intermediate hosts of SARS-CoV-2, however, further investigation is required to identify other intermediate hosts. SARS-CoV-2 binds to ACE2 through the spike glycoprotein on the surface of the virus and the spike protein of SARS-CoV-2 is activated by TMPRSS2. The pulmonary alveoli are infected with SARS-CoV-2, leading to injury of the type II pneumocyte. This can lead to acute lung injury, acute respiratory distress syndrome, severe pneumonia, severe hypoxemia, septic shock, and even multiple organ failure. b SARS-CoV-2 consists of the spike glycoprotein, envelope protein, membrane glycoprotein, and nucleocapsid protein. The RNA contains the genetic information that is passed to the next generation of virions which subsequently infect other host cells

Pathogenesis of COVID‑19

By infecting human bronchial epithelial cells, lung cells, and upper respiratory tract (URT) cells, SARS-CoV-2 can develop into a serious life-threatening respiratory disease, resulting in severe ARDS and permanent lung injury [70, 83]. Studies have found that the host receptor by which SARS-CoV-2 enters is the same as the host receptor for ACE2 [84]. SARS-CoV-2 consists of a spike glycoprotein, membrane glycoprotein, envelope protein, and nucleocapsid protein (Fig. 1b). SARS-CoV-2 binds to ACE2 through the spike glycoprotein on its surface (Fig. 1a, b), which can be modulated by transmembrane protease serine 2 (TMPRSS2) [85–87]. The symptoms of COVID-19 are generally divided into three stages: (1) the asymptomatic stage, which lasts for one to two days after infection, during which the virus attaches to the ACE2 receptor and starts to replicate. Innate immunity is lacking at this stage. (2) The URT infection stage, during which the virus migrates into the respiratory tract, triggering innate immunity. For most SARS-CoV-2 infected people, the infection is limited to URT. (3) The third and final stages involves ARDS and hypoxia, as the virus stresses and damages the alveoli. The alveoli release interferon (IFN), which sends signals to nearby unaffected cells to release antiviral peptides. These signal peptides cause resistance to the virus, and damaged cells release damage-associated molecular patterns, pathogen-associated molecular patterns, and secrete a series of cytokines that activate the innate immune response [88]. Macrophages respond to these signals by releasing more inflammatory factors, causing fluid filling between the capillaries and alveoli. In the process of killing the virus, neutrophils are recruited to the site of infection, possibly damaging healthy lung cells. During this period, the surfactants present in the alveoli are reduced. Phagocytes also release inflammatory cytokines, such as interleukin (IL)-1, IL-2, IL-6, IL-8, IL-12, tumor necrosis factor (TNF)-α, granulocyte colony-stimulating factor (G-CSF), transforming growth factor-β1 (TGF-β1), and monocyte chemoattractant protein-1 (MCP-1), which can cause an inflammatory response and subsequent lung infections [89, 90]. These cytokines also lead to increased levels of procoagulants.

Clinical features of COVID‑19

The most significant feature of the disease is its heterogeneity, as it ranges from asymptomatic infections to inducing critically ill symptoms [91, 92]. The incubation period of COVID-19 is calculated to be two weeks, and the median time is thought to be 4–5 days [1, 93]. A research report showed that 97.5% of COVID-19 patients developed symptoms within 11.5 days of SARS-CoV-2 infection [94]. Autopsy results have shown micro-thrombosis in multiple organ systems, such as the lung, heart, and kidney, which indicates that thrombosis precedes multiple organ dysfunction in severe cases [95]. Xu et al. found that patients with severe COVID-19 had respiratory failure and acute bilateral lung infiltration [96]. Hariri et al. further compared SARS-CoV-2 with SARS-CoV and H1N1 influenza and found that 88% of COVID-19 patients had acute diffuse alveolar damage, which is comparable to H1N1 (90%) and SARS (98%). Pulmonary micro-thrombosis was reported in 57%, 58%, and 24% of the SARS-CoV-2, SARS-CoV, and H1N1 infected patients, respectively [97]. In short, the main symptoms of COVID-19 include fever, headache, dry cough, chest tightness, sore throat, adverse gastrointestinal reactions, abdominal pain, diarrhea, hypoxemia, systemic muscle and joint aches, nasal congestion, rhinorrhea, liver damage, acute lung injury (ALI), metabolic acidosis, conjunctival congestion, ARDS, and severe pneumonia [98–100].

Main treatment strategies for COVID-19

Researchers are continuing to explore various methods to treat COVID-19. At present, large-scale drug screening, in-depth exploration of viral pathogenesis, application of rapid detection kits, and anti-inflammatory and antiviral therapies have been widely applied to prevent further spread of the disease [20, 56, 101, 102]. Extracorporeal membrane oxygenation (ECMO) is an invasive mechanical ventilation strategy mainly used to support continuous external breathing and circulation in critically ill patients with critical cardiopulmonary failure [103]. However, these devices are often expensive, and resources of ECMO are limited globally. It is urgent that effective treatments to reduce mortality and improve clinical outcomes are developed, especially for severe and critically ill patients. The main measures to alleviate COVID-19 in patients (especially severe patients) include: (1) plasma therapy for convalescent patients; (2) antiviral drug therapy; (3) immune-mediated therapy; (4) glucocorticoid therapy; (5) inhibition of the binding of human cell surface receptor ACE2 protein to the virus; (6) inhibition of key enzymes in the virus; (7) metabolic support and nutrition therapy; (8) stem cell therapy; (9) integrated Chinese and Western medical therapies; (10) probiotic therapy; (11) artificial liver therapy; and (12) lung transplantation [104–112]. In addition, blood purification systems have also been investigated. These studies speed up the screening of effective drugs to prevent mild cases of the disease from developing into severe cases, and improve the treatment regimens for severe and critically ill COVID-19 patients.

Underlying mechanisms of the MSCs used to treat COVID-19

Rapid developments in regenerative medicine have led scientists to study and isolate MSCs from different human tissues, and they have been utilized for a variety of purposes such as the repair of lung tissues [113–115]. MSCs can be utilized to treat many common lung diseases, such as ALI [116–118], idiopathic pulmonary fibrosis [119–121], ARDS [122–124], lung cancer [125–127], asthma [128, 129], and chronic obstructive pulmonary disease (COPD) [130, 131]. A schematic diagram of this process is shown in Fig. 2.

Fig. 2.

MSC-based therapies for pre-clinical studies in lung diseases. MSCs can be obtained from most human tissues, including bone marrow (BM), adipose tissue (AD), umbilical cord (UC), Wharton’s jelly (WJ), menstrual blood, placenta, dental pulp, and lung. MSCs can treat many lung diseases, such as acute lung injury, idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS), lung cancer, asthma, and chronic obstructive pulmonary disease (COPD)

Early reports indicated that MSCs could be used to treat various lung diseases by promoting repair and regulating inflammation in the lung [132–134]. While there are differences in the mechanism of different lung diseases, MSCs have shown positive effects in preclinical studies. Recently, clinical studies have found that the cytokine profile of COVID-19 patients undergoes great changes after treatments with MSCs [135–138], which may lead to immune imbalances and multiple lung dysfunctions. The main mechanisms of action for MSCs in the treatment of COVID-19 are shown in Fig. 3.

Fig. 3.

The main mechanisms of action for MSCs in the treatment of COVID-19. The main mechanisms by which MSCs exert their effect in the treatment of lung-related diseases is through their differentiation potential, immune regulation, secretion of anti-inflammatory factors, migration and homing, anti-apoptotic properties, antiviral effects, and through extracellular vesicles

Differentiation potential

Under certain conditions, the addition of special inducing factors can guide MSCs to differentiate into nerve, muscle, and epithelial cells, thus proving their differentiation potential into endodermal and neuro-dermal tissues [139]. Previous studies have shown that MSCs may have the ability to transdifferentiate into alveolar epithelial cells [115, 140]. Furthermore, transplanted MSCs were found to differentiate into respiratory epithelial cells to compensate for the functional alveolar epithelial cell barrier in diseased tissues and improve local damage. Recently, Liu et al. induced the differentiation of hUC-MSCs into type 2 alveolar epithelial cells and transplanted differentiated cells into pulmonary fibrosis mice. They found that differentiated cells could reduce the mortality of bleomycin-induced pulmonary fibrosis mice [141]. Therefore, it was determined that MSCs could be applied to treat various lung diseases, including lung injury and inflammation caused by SARS-CoV-2 infection, due to their potential to differentiate into alveolar epithelial cells.

Immune regulation

The role of MSCs in immune regulation has been extensively studied. MSCs can regulate both innate and adaptive immunity by interacting with various immune cells [56, 58, 142, 143]. MSCs can also regulate innate immune responses by targeting DCs, natural killer (NK) cells, innate T helper 17 cells, neutrophils, mast cells, and macrophages [56]. Due to the immune escape mechanism of SARS-CoV-2, the virus partly evades the recognition and attack of the innate immune system, causing adaptive immunity to play a key role. MSCs mainly regulate adaptive immunity by targeting T lymphocytes, B lymphocytes, antigen-presenting cells (APCs), DCs, NK cells, and regulatory T cells (Tregs) [58]. In addition, the local immunity of the lung is mediated by CD4⁺ T cells and CD8⁺ T cells, which can quickly kill foreign viruses during infection [144], implying that the adaptive immunity regulation mechanism by MSCs may be applied in the treatment of COVID-19. Although the human body’s dual immune system can mostly prevent the virus from invading, SARS-CoV-2 has an escape mechanism. After MSCs are injected into the body, the immune regulation mechanism allows additional mobilization of various immune cells, which further prevents the invasion of SARS-CoV-2. As a response to inflammatory mediators, MSCs mainly produce a variety of soluble factors that regulate the immune response, including PGE2, TGF-β1, indoleamine 2,3-dioxygenase (IDO), nitric oxide (NO), HGF, and IL-10 [143].

Secretion of anti-inflammatory factors

The inhibition of inflammation is another important function of MSCs. MSCs secrete a variety of soluble factors through paracrine action, collectively called secretory bodies. Studies have found that many inflammatory factors were increased in the blood of COVID-19 patients, such as IFN-γ, IFN inducible protein-10, and MCP-1. In addition, the concentration of inflammatory factors, such as G-CSF, MCP-1, and TNF-α, in intensive care unit (ICU) patients have been shown to be significantly higher than in non-ICU patients [145]. Several studies have shown that the therapeutic effect of MSCs is mainly mediated by the secretion of paracrine factors, including growth factors, chemokines, and cytokines [146, 147]. The cytokine storm in patients with severe COVID-19 causes the release of nitric oxide, which affects the normal contraction and diastolic functions of the blood vessels, resulting in hypotension, multiple organ hypoxia, and ARDS [148, 149]. SARS-CoV-2 causes a cytokine storm and secretes high levels of pro-inflammatory cytokines, such as IL-1β, IL-1RA, and IL-2, in the lungs. As well as, IL-6, IL-7, G-CSF, IFN, TNF, PI3-K/AKT, Rac1, alveolar cavity neutrophils, and infiltration of macrophages [145, 150, 151]. Ellison-Hughes et al. summarized how MSCs potentially alleviate damage caused by COVID-19-induced cytokine storms, and explored how MSC transplantation facilitated the reduction of long-term complications in COVID-19 patients, including lung injury repair and partial functional lung cell regeneration [152]. In addition, our group has found that menstrual blood-derived MSCs improve lung function by secreting anti-inflammatory cytokines both in ALI and pulmonary fibrosis mouse models [153, 154]. The main mechanism of MSC-based therapy for COVID-19 is mediated by the production of anti-inflammatory molecules and reductions in the secretion of inflammatory factors. In summary, inflammatory factors are reduced, and anti-inflammatory factors are increased by MSC infusion. Therefore, the anti-inflammatory effects of MSCs can be utilized in the treatment of COVID-19.

Migration and homing

Migration and homing are unique characteristics of MSCs. Although not a direct effect of MSCs, their chemotaxis enables them to target injured lung tissues [155, 156], allowing a further exertion of their therapeutic effects. MSCs can migrate to the site of injury after intravenous or local injection. Migration and homing is a multi-step process that includes three different stages: (1) direct administration or cell recruitment and entering the blood circulation; (2) extravasation through the concentration gradient of lymphocytes near the lesion; and (3) migration to the damaged interstitium of the lung [157]. This process is mainly induced by chemokines released from injured or inflamed lung tissues, which triggers the migration and homing of MSCs [156, 158]. G-CSF is a common pharmacological agent used to induce mobilization, which acts through the expansion of the medullary compartment, activity of neutrophil elastase, release of cathepsin G, and reduction of stromal cell-derived factor-1 (SDF-1) levels. Stabilization of hypoxia-inducible factor-1 α (HIF-1α) increases mobilization by sinus-shaped vasodilatation caused by an increase in VEGF levels. In short, the main factors for MSC migration and homing include SDF-1, CXCR4, G-CSF, HIF-1α, PGE2, peroxisome proliferator-activated receptor (PPAR)-γ, MCP-1, CXCR7, CCR2, α4/β1 integrin, and CD44 molecules [158]. In addition, MSCs can recognize some endothelial cell adhesion molecules, including palmitate G protein, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1, thereby mediating migration and homing.

Anti-apoptotic properties

Apoptosis is a defense mechanism of the host against the source of infection, and it plays a vital role in the interactions between the host and pathogen. MSCs, however, have the ability to resist apoptosis. Studies of SARS-CoV-2 patients have observed different degrees of apoptosis during the viral infection stage [159]. Lymphopenia caused by immune cell failure due to T cell exhaustion and apoptosis has also been observed in the same patient population [160]. Therefore, it is particularly important to effectively control apoptosis in COVID-19 patients. MSCs inhibit cell apoptosis resulting from hypoxia, chemical stimulation, mechanical damage, and radiation. The anti-apoptotic effect of MSCs has been fully demonstrated in cardiac ischemia and neurological and pulmonary diseases [161]. Bernard et al. found that HGF and KGF released by MSCs protected alveolar epithelial cells from apoptosis by increasing B-cell leukemia/lymphoma-2 (Bcl-2) expression and inhibiting HIF-1α expression [162]. In hypoxia-induced apoptosis, MSCs induced the expression of several factors, including VEGF, TGF-β1, and HGF, to reduce the apoptosis of endothelial cells. The anti-apoptotic properties of MSCs against lung diseases mean that MSCs could potentially be used as a treatment for COVID-19.

Antiviral effects

Antiviral effects are another feature of MSCs. MSCs inhibit virus replication, virus shedding, and virus-induced lung epithelial cell damage [163]. IDO [164] and antimicrobial peptide LL37 [165] produced by MSCs have been shown to inhibit influenza virus replication through viral membrane degradation. Khatri et al. studied the swine influenza virus pneumonia model and showed that intra-tracheal administration of MSC-derived EVs could effectively reduce virus replication in lung epithelial cells [163]. Additional studies have shown that SARS-CoV2 enters cells through the widely distributed ACE2 receptors, including alveolar and capillary endothelial cells. RNA-sequence analysis has found that transplanted MSCs are ACE2 negative and can therefore resist SARS-CoV-2 infection [166]. In addition, MSCs retained their immunomodulatory potential, which supports their potential applicability for treating COVID-19 [65]. Recently, Avanzani et al. demonstrated the role of SARS-CoV-2 infection in MSCs derived from various human tissues. These findings support the use of MSCs as a potential method by which to downregulate immune over-activation in COVID-19 patients and reduce fibrosis in patients recovering from acute SARS-CoV-2 infections [66]. The mechanisms by which MSCs inhibit the replication and infection of SARS-CoV-2, however, are unknown and require further investigation.

MSC-EVs

EVs are mainly divided into extracellular bodies, microvesicles, and apoptotic bodies [167]. As a medium for cell-to-cell communication, EVs play a vital role in cell-to-cell transmission under pathophysiological conditions, including the transmission of RNAs, antigen presentation, tumor immune regulation, and drug loading [168–170]. This strategy bypasses most of the safety issues related to cell therapy, such as cancer cell contamination and cell proliferation hazards. Recent studies have shown that EVs derived from MSCs can improve bronchopulmonary dysplasia, ARDS, COPD, idiopathic pulmonary fibrosis, COVID-19, and pulmonary hypertension [171–173]. Morrison et al. showed that MSCs regulate macrophages in ALI through EV-mediated mitochondrial transfer [174]. Functional mitochondria transferred through MSC-EVs enhanced the mitochondrial function of primary human alveolar cells and their ability to repair lung injury [163]. EVs can reduce pulmonary inflammation by reducing the recruitment of neutrophils and macrophages and the level of MIP-2 [175]. At the same time, EVs can reduce pulmonary edema and endothelial permeability. In a mouse model of lung ischemia/reperfusion injury, the anti-apoptotic molecule miR-21-5p was found to be the main link to the protective effect of the MSC-EVs [176]. Specifically, exogenous miR-21-5p reduces lung tissue oxidative stress-induced apoptosis by targeting the phosphatase and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) [176]. These findings strongly support the use of MSC-derived EVs as a treatment for COVID-19.

Clinical studies of MSC transplantation to treat COVID-19

At present, there are no effective treatments available for COVID-19 patients who are classified as critically ill. However, stem cell transplantation is an emergency treatment method that could be used to address this, and is currently being tested in clinical trials in research institutions around the world [177–179]. As of Nov 17, 2021, according to Clinicaltrials.gov (https://www.clinicaltrials.gov/; search for “COVID-19” and “mesenchymal stem cell”), a total of 74 MSCs are currently being verified in clinical trials to treat COVID-19 (Table 1). Among these MSC clinical trials (Table 1), 22 were using UC-MSCs, 15 AD-MSCs, and 11 BM-MSCs. There were also 7 WJ, 2 dental pulp, 1 cord blood, 1 menstrual blood, 1 placental, and 1 mucosal-derived MSC clinical trials. In addition to those using known sources for the MSCs, there were also 14 clinical trials using MSCs from unknown tissue sources. At present, UC, BM, and AD are the major sources of MSCs used in the clinical trials for the treatment of COVID-19. Most trials were in their early stages, as 19 were phase 1, 25 were phase 1/2, 24 were phase 2, 1 was a phase 2/3 combined trial, 1 was phase 3, and 4 were unspecified.

Table 1.

Cell source and trial phase of MSC clinical trials for treating COVID-19

Order	NCT number	Title	First posted	Status	Conditions	Source	Phase
1	NCT05019287	Menstrual blood stem cells in severe COVID-19	August 24, 2021	Completed	COVID-19	Menstrual blood-derived MSC	Phase 1 Phase 2
2	NCT05017298	Clinical study for subjects with COVID-19 using allogeneic adipose tissue-derived mesenchymal stem cells	August 23, 2021	Not yet recruiting	COVID-19	AD-MSCs	Phase 1 Phase 2
3	NCT04992247	Study of allogeneic adipose-derived mesenchymal stem cells to treat post-COVID-19 “Long Haul” pulmonary compromise (BR)	August 5, 2021	Not yet recruiting	COVID-19	AD-MSCs	Phase 2
4	NCT04909892	Study of allogeneic adipose-derived mesenchymal stem cells to treat post-COVID-19 “Long Haul” pulmonary compromise	June 2, 2021	Not yet recruiting	COVID-19	AD-MSCs	Phase 2
5	NCT04869397	Treatment of respiratory complications associated with COVID-19 using umbilical cord mesenchymal stromal cells (ProTrans19 +)	May 3, 2021	Not yet recruiting	COVID-19	WJ-MSCs	Phase 2
6	NCT04865107	Cellular immuno-therapy for COVID-19 ARDS randomized clinical trial (CIRCA-19 RCT)	April 29, 2021	Recruiting	COVID-19|Acute Respiratory Distress Syndrome	UC-MSCs	Phase 2
7	NCT04780685	A phase II study in patients with moderate to severe ARDS due to COVID-19	March 3, 2021	Recruiting	COVID-19	BM-MSCs	Phase 2
8	NCT04753476	Treatment of severe COVID-19 patients using secretome of hypoxia-mesenchymal stem cells in Indonesia	February 15, 2021	Recruiting	COVID-19|Cytokine Storm	N/A	Phase 2
9	NCT04728698	Study of intravenous administration of allogeneic adipose-derived mesenchymal stem cells for COVID-19-induced acute respiratory distress	January 28, 2021	Not yet recruiting	COVID-19|ARDS	AD-MSCs	Phase 2
10	NCT04713878	Mesenchymal stem cells therapy in patients with COVID-19 pneumonia	January 19, 2021	Completed	Coronavirus disease 2019 (COVID-19) Pneumonia	N/A	N/A
11	NCT04629105	Regenerative medicine for COVID-19 and flu-elicited ARDS Using longeveron mesenchymal stem cells (LMSCs) (RECOVER)	November 16, 2020	Recruiting	ARDS, Human|COVID-19	N/A	Phase 1
12	NCT04625738	Efficacy of infusions of MSC from Wharton jelly in the SARS-Cov-2 (COVID-19)-related acute respiratory distress syndrome	November 12, 2020	Not yet recruiting	COVID-19 ARDS	WJ-MSCs	Phase 2
13	NCT04611256	Mesenchymal stem cells in patients diagnosed with COVID-19	November 2, 2020	Recruiting	COVID-19	AD-MSCs	Phase 1
14	NCT04573270	Mesenchymal stem cells for the treatment of COVID-19	October 5, 2020	Completed	COVID-19|Prophylaxis	UC-MSCs	Phase 1
15	NCT04565665	Cord blood-derived mesenchymal stem cells for the treatment of COVID-19-related acute respiratory distress syndrome	September 25, 2020	Recruiting	COVID-19 Infection|COVID-19-Associated Acute Respiratory Distress Syndrome	Cord blood MSCs	Phase 1
16	NCT04537351	The MEseNchymal COVID-19 trial: a pilot study to investigate early efficacy of MSCs in adults with COVID-19	September 3, 2020	Recruiting	COVID-19|Acute Respiratory Distress Syndrome	N/A	Phase 1 Phase 2
17	NCT04535856	Therapeutic study to evaluate the safety and efficacy of DW-MSC in COVID-19 patients	September 2, 2020	Completed	COVID-19|Coronavirus Infection|SAR	N/A	Phase 1
18	NCT04527224	Study to evaluate the efficacy and safety of AstroStem-V in treatment of COVID-19 pneumonia	August 26, 2020	Not yet recruiting	COVID-19	AD-MSCs	Phase 1 Phase 2
19	NCT04525378	MSC-based therapy in COVID-19-associated acute respiratory distress syndrome	August 25, 2020	Recruiting	COVID-19|ARDS, Human	N/A	Phase 1
20	NCT04524962	Study of descartes-30 in acute respiratory distress syndrome	August 24, 2020	Recruiting	Acute Respiratory Distress Syndrome|COVID-19	N/A	Phase 1 Phase 2
21	NCT04522986	An exploratory study of ADR-001 in Patients with severe pneumonia caused by SARS-CoV-2 infection	August 21, 2020	Not yet recruiting	Severe Acute Respiratory Syndrome Coronavirus 2	AD-MSCs	Phase 1
22	NCT04494386	Umbilical cord lining stem cells (ULSC) in patients With COVID-19 ARDS	July 31, 2020	Recruiting	COVID-19|Corona Virus Infection|SARS-CoV Infection|ARDS|Coronavirus	UC-MSCs	Phase 1 Phase 2
23	NCT04492501	Investigational treatments for COVID-19 in tertiary care hospital of Pakistan	July 30, 2020	Completed	COVID-19|Cytokine Release Syndrome|Critical Illness|ARDS	BM-MSCs	N/A
24	NCT04490486	Umbilical cord tissue (UC)-derived mesenchymal stem cells (MSCs) versus placebo to treat acute pulmonary inflammation due to COVID-19	July 29, 2020	Not yet recruiting	COVID-19|Acute Respiratory Distress Syndrome|Corona Virus Infection	UC-MSCs	Phase 1
25	NCT04467047	Safety and feasibility of allogenic MSC in the treatment of COVID-19	July 10, 2020	Not yet recruiting	COVID-19|SARS-CoV2	BM-MSCs	Phase 1
26	NCT04466098	Multiple dosing of mesenchymal stromal cells in patients with ARDS (COVID-19)	July 10, 2020	Active, not recruiting	Acute Respiratory Distress Syndrome|ARDS (Moderate or Severe)|COVID-19 Pneumonia	N/A	Phase 2
27	NCT04461925	Treatment of coronavirus COVID-19 pneumonia (pathogen SARS-CoV-2) with cryopreserved allogeneic P_MMSCs and UC-MMSCs	July 8, 2020	Recruiting	COVID-19 Pneumonia	Placenta-derived MSCs/UC-MSCs	Phase 1 Phase 2
28	NCT04457609	Administration of Allogenic UC-MSCs as adjuvant therapy for critically ill COVID-19 patients	July 7, 2020	Recruiting	COVID|Pulmonary Infection|SARS-CoV2	UC-MSCs	Phase 1
29	NCT04456361	Use of mesenchymal stem cells in acute respiratory distress syndrome caused by COVID-19	July 2, 2020	Active, not recruiting	ARDS, Human|COVID-19	WJ-MSCs	Early Phase 1
30	NCT04452097	Use of hUC-MSC product (BX-U001) for the treatment of COVID-19 with ARDS	June 30, 2020	Not yet recruiting	COVID-19|ARDS|Acute Respiratory Distress Syndrome	UC-MSCs	Phase 1 Phase 2
31	NCT04447833	Mesenchymal stromal cell therapy for the treatment of acute respiratory distress syndrome	June 25, 2020	Active, not recruiting	ARDS, Human|COVID	BM-MSCs	Phase 1
32	NCT04445220	A study of cell therapy in COVID-19 subjects with acute kidney injury who are receiving renal replacement therapy	June 24, 2020	Recruiting	COVID-19|Acute Kidney Injury	N/A	Phase 1 Phase 2
33	NCT04445454	Mesenchymal stromal cell therapy for severe COVID-19 infection	June 24, 2020	Recruiting	Coronavirus Infection	BM-MSCs	Phase 1 Phase 2
34	NCT04444271	Mesenchymal stem cell infusion for COVID-19 infection	June 23, 2020	Recruiting	COVID-19	BM-MSCs	Phase 2
35	NCT04437823	Efficacy of intravenous infusions of stem cells in the treatment of COVID-19 patients	June 18, 2020	Recruiting	Coronavirus Infection	UC-MSCs	Phase 2
36	NCT04429763	Safety and efficacy of mesenchymal stem cells in the management of severe COVID-19 pneumonia	June 12, 2020	Not yet recruiting	COVID-19	UC-MSCs	Phase 2
37	NCT04428801	Autologous adipose-derived stem cells (AdMSCs) for COVID-19	June 11, 2020	Not yet recruiting	COVID-19	AD-MSCs	Phase 2
38	NCT04416139	Mesenchymal stem cell for acute respiratory distress syndrome due for COVID-19	June 4, 2020	Recruiting	COVID-19	UC-MSCs	Phase 2
39	NCT04399889	hCT-MSCs for COVID-19 ARDS	May 22, 2020	Recruiting	COVID|Coronavirus Infection|COVID-19	UC-MSCs	Phase 1 Phase 2
40	NCT04400032	Cellular immuno-therapy for COVID-19 acute respiratory distress syndrome—Vanguard	May 22, 2020	Recruiting	Acute Respiratory Distress Syndrome|COVID-19	BM-MSCs	Phase 1
41	NCT04397796	Study of the safety of therapeutic Tx With immunomodulatory MSC in adults With COVID-19 infection requiring mechanical ventilation	May 21, 2020	Recruiting	COVID	BM-MSCs	Phase 1
42	NCT04398303	ACT-20 in patients with severe COVID-19 pneumonia	May 21, 2020	Not yet recruiting	COVID-19 Pneumonia	UC-MSCs	Phase 1 Phase 2
43	NCT04392778	Clinical use of stem cells for the treatment of COVID-19	May 19, 2020	Recruiting	COVID-19|Pneumonia|Multiple Organ Failure|Coronavirus Infection	N/A	Phase 1 Phase 2
44	NCT04390152	Safety and efficacy of intravenous Wharton’s jelly-derived mesenchymal stem cells in acute respiratory distress syndrome due to COVID-19	May 15, 2020	Recruiting	Acute Respiratory Distress Syndrome	WJ-MSCs	Phase 1 Phase 2
45	NCT04390139	Efficacy and safety evaluation of mesenchymal stem cells for the treatment of patients with respiratory distress due to COVID-19	May 15, 2020	Recruiting	COVID-19|SARS-CoV 2|Adult Respiratory Distress Syndrome	WJ-MSCs	Phase 1 Phase 2
46	NCT04382547	Treatment of COVID-19-associated pneumonia with allogenic pooled olfactory mucosa-derived mesenchymal stem cells	May 11, 2020	Enrolling by invitation	COVID|COVID-19|Coronavirus|Pneumonia|Pneumonia, Viral|Pneumonia, Interstitial|SARS-CoV2	Mucosa-derived MSCs	Phase 1 Phase 2
47	NCT04377334	Mesenchymal stem cells (MSCs) in inflammation-resolution programs of coronavirus disease 2019 (COVID-19)-induced acute respiratory distress syndrome (ARDS)	May 6, 2020	Not yet recruiting	ARDS|COVID-19	BM-MSCs	Phase 2
48	NCT04371601	Safety and effectiveness of mesenchymal stem cells in the treatment of pneumonia of coronavirus disease 2019	May 1, 2020	Active, not recruiting	COVID-19 Pneumonia	UC-MSCs	Early Phase 1
49	NCT04371393	MSCs in COVID-19 ARDS	May 1, 2020	Active, not recruiting	Mesenchymal Stromal Cells|Remestemcel-L|Acute Respiratory Distress Syndrome|COVID	N/A	Phase 3
50	NCT04366323	Clinical trial to assess the safety and efficacy of intravenous administration of allogeneic adult mesenchymal stem cells of expanded adipose tissue in patients with severe pneumonia due to COVID-19	April 28, 2020	Active, not recruiting	SARS-CoV2	AD-MSCs	Phase 1 Phase 2
51	NCT04366271	Clinical trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19	April 28, 2020	Recruiting	COVID	UC-MSCs	Phase 2
52	NCT04366063	Mesenchymal stem cell therapy for SARS-CoV-2-related acute respiratory distress syndrome	April 28, 2020	Recruiting	COVID-19	N/A	Phase 2 Phase 3
53	NCT04362189	Efficacy and safety study of allogeneic HB-adMSCs for the treatment of COVID-19	April 24, 2020	Active, not recruiting	COVID-19	AD-MSCs	Phase 2
54	NCT04361942	Treatment of severe COVID-19 pneumonia with allogeneic mesenchymal stromal cells (COVID_MSV)	April 24, 2020	Recruiting	COVID-19 Pneumonia	N/A	Phase 2
55	NCT04355728	Use of UC-MSCs for COVID-19 patients	April 21, 2020	Completed	Corona Virus Infection|ARDS|ARDS, Human|Acute Respiratory Distress Syndrome|COVID-19	UC-MSCs	Phase 1 Phase 2
56	NCT04352803	Adipose mesenchymal cells for abatement of SARS-CoV-2 RESPIRATORY COMPROMISE IN COVID-19 Disease	April 20, 2020	Not yet recruiting	COVID-19 Pneumonia|Cyotokine Storm	AD-MSCs	Phase 1
57	NCT04348435	A randomized, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of hope biosciences allogeneic mesenchymal stem cell therapy (HB-adMSCs) to provide protection against COVID-19	April 16, 2020	Not yet recruiting	COVID-19	AD-MSCs	Phase 2
58	NCT04349631	A clinical trial to determine the safety and efficacy of hope biosciences autologous mesenchymal stem cell therapy (HB-adMSCs) to provide protection against COVID-19	April 16, 2020	Active, not recruiting	COVID-19	AD-MSCs	Phase 2
59	NCT04348461	BAttLe against COVID-19 using Mesenchymal stromal cells	April 16, 2020	Suspended	COVID|Respiratory Distress Syndrome	AD-MSCs	Phase 2
60	NCT04346368	Bone marrow-derived mesenchymal stem cell treatment for severe patients with coronavirus disease 2019 (COVID-19)	April 15, 2020	Not yet recruiting	Coronavirus Disease 2019 (COVID-19)	BM-MSCs	Phase 1 Phase 2
61	NCT04345601	Mesenchymal stromal cells for the treatment of SARS-CoV-2-induced acute respiratory failure (COVID-19 disease)	April 14, 2020	Recruiting	SARS-CoV2|Acute Respiratory Distress Syndrome|COVID-19	BM-MSCs	Phase 1 Phase 2
62	NCT04341610	ASC therapy for patients with severe respiratory COVID-19	April 10, 2020	Withdrawn	Respiratory Tract Diseases	AD-MSCs	Phase 1 Phase 2
63	NCT04339660	Clinical research of human mesenchymal stem cells in the treatment of COVID-19 pneumonia	April 9, 2020	Recruiting	COVID-19	UC-MSCs	Phase 1 Phase 2
64	NCT04336254	Safety and efficacy study of allogeneic human dental pulp mesenchymal stem cells to treat severe COVID-19 patients	April 7, 2020	Recruiting	COVID-19	Dental pulp MSCs	Phase 1 Phase 2
65	NCT04333368	Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-related ARDS	April 3, 2020	Active, not recruiting	Severe Acute Respiratory Syndrome Coronavirus 2|Severe Acute Respiratory Distress Syndrome	WJ-MSCs	Phase 1 Phase 2
66	NCT04315987	NestaCell® mesenchymal stem cell to treat patients with Severe COVID-19 pneumonia	March 20, 2020	Not yet recruiting	COVID-19 Pneumonia	N/A	Phase 2
67	NCT04313322	Treatment of COVID-19 patients using Wharton’s jelly-mesenchymal stem cells	March 18, 2020	Recruiting	Use of Stem Cells for COVID-19 Treatment	WJ-MSCs	Phase 1
68	NCT04302519	Novel coronavirus-induced severe pneumonia treated by dental pulp mesenchymal stem cells	March 10, 2020	Not yet recruiting	COVID-19	Dental pulp MSCs	Early Phase 1
69	NCT04293692	Therapy for pneumonia patients infected by 2019 novel coronavirus	March 3, 2020	Withdrawn	COVID-19	UC-MSCs	N/A
70	NCT04288102	Treatment with human umbilical cord-derived mesenchymal stem cells for severe coronavirus disease 2019 (COVID-19)	February 28, 2020	Completed	Coronavirus Disease 2019(COVID-19)	UC-MSCs	Phase 2
71	NCT04273646	Study of human umbilical cord mesenchymal stem cells in the treatment of severe COVID-19	February 18, 2020	Not yet recruiting	2019 Novel Coronavirus Pneumonia|COVID-19	UC-MSCs	N/A
72	NCT04269525	Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) treatment for the 2019-novel coronavirus (nCOV) pneumonia	February 13, 2020	Recruiting	Pneumonia, Viral|Pneumonia, Ventilator-Associated	UC-MSCs	Phase 2
73	NCT04252118	Mesenchymal stem cell treatment for pneumonia patients infected with COVID-19	February 5, 2020	Recruiting	COVID-19	UC-MSCs	Phase 1
74	NCT03042143	Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) (COVID-19)	February 3, 2020	Recruiting	Acute Respiratory Distress Syndrome	UC-MSCs	Phase 1 Phase 2

BM bone marrow, AD adipose tissue, UC umbilical cord, WJ Wharton’s jelly

Since most of these clinical trials are ongoing, the available clinical research results are currently limited. Leng et al. used MSCs to treat COVID-19 patients [180] and investigated the inflammation, immune function, and adverse reactions of seven patients within 14 days after MSC transplantation. Expression of TNF-α was reduced, and the expression of IL-10 was enhanced. They further reported the absence of any adverse events and concluded that MSCs effectively ameliorated the functional outcomes of all seven patients. In addition, our group studied the therapeutic effects of menstrual blood-derived MSCs in treating COVID-19 in a multicenter, open-label, non-randomized, parallel-controlled exploratory trial [181]. The mortality of patients in the MSC group was significantly lower (7.69% in the MSC group and 33.33% in the control group). The dyspnea and SpO2 significantly improved after MSC infusion on days 1, 3, and 5. Chest imaging results of the experimental group also showed improvement within 1 month of the MSC treatment. The incidence of most adverse events did not differ between the MSC and control groups [181]. Another study conducted by Meng et al. included 18 patients with moderate to severe COVID-19, nine of whom received UC-MSC infusion therapy [182]. From their results, two patients who received UC-MSCs experienced transient facial flushing and fever 12 h after infusion, and one patient experienced transient hypoxia. Recently, the same group conducted a phase 2 study and found that when compared with the placebo group, UC-MSCs significantly decreased the proportion of solid component lesion volume [183]. Lanzoni et al. conducted a double-blind, phase 1/2a randomized controlled trial in which 24 subjects receiving UC-MSC treatment were followed up for COVID-19 and ARDS for 1 month [184]. They found that the UC-MSC infusion consistently and effectively reduced a group of inflammatory cytokines related to COVID-19 “cytokine storms”, thus improving patients’ survival and recovery time [184]. Shu et al. studied the possible impact of intravenous UC-MSCs on COVID-19 patients and showed that the transplantation of human UC-MSCs shortened the time for clinical improvement when compared to the placebo group. The incidence of critically ill progression after UC-MSC treatment was 0, and the 28-day mortality rate was 0. In the control group, four critically ill patients were treated with invasive ventilation, of which 3 died, and the 28-day mortality rate was 10.34%. At the same time, the clinical symptoms of fatigue, weakness, and respiratory distress were significantly reduced after UC-MSC treatment [185]. Sánchez-Guijo et al. demonstrated the safety of AD-MSCs with the transplantation of 1 × 10⁶/kg of AD-MSCs 1–3 times in 13 patients with severe COVID-19 [186]. The study found that the clinical symptoms of 9 patients (70%) improved at a median follow-up of 16 days after the first AD-MSC administration. Feng et al. reported that the mortality rate of COVID-19 patients was 6.25% after UC-MSC infusion. The estimated cytokine levels changed within the normal range, the radiological appearance (ground glass opacity) was improved, and the lymphocyte count and lymphocyte subpopulation (CD4⁺ T cells, CD8⁺ T cells, and NK cells) counts were restored after transplantation [187]. Hashemian et al. proved that no serious adverse reactions occurred 24–48 h after transplantation of the UC-MSCs or placental MSCs [188]. They further observed that 48–96 h after the first infusion in 7 patients, dyspnea eased and SpO2 increased. Of these 7 patients, 5 were discharged from the ICU within 2–7 days (average of 4 days). The serum levels of the TNF-α, IL-8, and C-reactive protein (CRP) were significantly reduced in all six survivors. The six survivors had no symptoms of dyspnea 60 days post infusion. The radiological parameters of the lung CT showed clear signs of recovery [188].

Clinical data increasingly show that “not all MSCs are equal” as MSCs from different tissues express different factors at different levels and have different functions (Table 2). However, regardless of the MSC type, they were all found to exert a significant improvement in lung function or reduced mortality when intravenously transplanted. Although there are many types of MSC injection, the most popular method is intravenous infusion. When compared with different sources of MSC-based therapies in COVID-19, the initial results mainly rely on improving lung function, serum indexes, and inflammation indexes. Currently, there is still no systematic contrast regarding treatment differences with various MSCs. For example, menstrual blood MSCs were used, and a total of 9 × 10⁷ cells showed a rapid improvement in breathing difficulties [181]. AD-MSCs were used in a total of 1–3 × 10⁶ /kg cells to treat COVID-19 [186]. The UC-MSCs used a range from a total of 9 × 10⁷ cells [182] to a total of 4 × 10⁸ cells [187]. Generally, MSCs should be injected 2–4 times to persistently exert their function. In addition to the above clinical studies, some case reports have shown that MSCs (including UC-MSCs, menstrual blood MSCs, and WJ-MSCs) are a promising method for the treatment of COVID-19, especially critically ill patients [189–192]. Although these preliminary clinical results are encouraging, more clinical data are required to further clarify the underlying mechanisms and potential targets to improve clinical applications.

Table 2.

Clinical studies of MSC therapy in patients for treating COVID-19

Title	Clinical trial no.	No. of MSC injection	No. of control group	Time for MSC treatment	Therapeutic effect	Major affiliation	Sources	Cells for each time	times	Transplantation	Ref
Transplantation of ACE2—mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia	ChiCTR2000029990	7	3	14 days	The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation Decrease TNF-α and increase IL-10 in 14 days after MSC transplantation	School of Life Sciences, Shanghai University, Shanghai, China	N/A	1 × 106 cells/kg	1	Intravenous	[180]
Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial	ChiCTR2000029606	26	18	1 month	Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = 0.048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5	State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, People’s Republic of China	Menstrual blood-derived MSCs	3*107	3	Intravenous	[181]
Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial	NCT04252118	9	9	28 days	Two patients receiving UC-MSCs developed transient facial flushing and fever, and one patient developed transient hypoxia at 12 h post UC-MSCs transfusion	Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China	UC-MSCs	3 × 107 cells	3	Intravenous	[182]
Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial	NCT04288102	65	35	28d	Reduced the proportions of solid component lesion volume. The 6-min walk test showed an increased distance in patients treated with UC-MSCs	Department of Infectious Diseases, Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing, China	UC-MSCs	4 × 107 cells	4	Intravenous	[183]
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial	NCT04355728	12	12	31 days	UC-MSC treatment was associated with a significant decrease in a set of inflammatory cytokines involved in the COVID-19 “cytokine storm.”, and UC-MSC treatment was associated with significantly improved patient survival and time to recovery	Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, Florida, United States	UC-MSCs	1 × 108 cells	2	intravenous	[184]
Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells	ChiCTR2000031494	12	29	28 days	The incidence of progression from severe to critical illness and the 28-day mortality rate were 0 in the hUC-MSC treatment group, while 4 patients in the control group deteriorated to critical condition and received invasive ventilation; 3 of them died, and the 28-day mortality rate was 10.34% human UC-MSC transplantation shortened time to clinical improvement in the transplanted group compared to the control group	Department of Respiratory Medicine, Sir Run Run Hospital, Nanjing Medical University, Nanjing 211,166, Jiangsu, China	UC-MSCs	2 × 106 cells/kg	1	Intravenous	[185]
Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study	NCT04348461	13	0	28 days	After AT-MSC treatment, inflammation parameters are reduced During the median follow-up 16 days (IQR 9 days) after the first administration, 9 patients (70%) had improved clinical symptoms	Cell Therapy Area, Hematology Department, IBSAL-Hospital Universitario de Salamanca, Universidad de Salamanca, Salamanca, Spain	AD-MSCs	1 × 106 /kg	1–3	Intravenous	[186]
Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: A pilot study	NCT04269525	16	0	28 days	The mortality of enrolled patients was 6.25%, whereas the historical mortality rate was 45.4% The level of cytokines estimated varied in the normal range, the radiological presentations (ground glass opacity) were improved and the lymphocyte count and lymphocyte subsets (CD4 + T cells, CD8 + T cells and NK cells) count showed recovery after transplantation	Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China	UC-MSCs	1 × 108 cells	4	Intravenous	[187]
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series	IRCT20200217046526N2	11	0	60 days	No serious adverse events reported 24–48 h after the cell infusions. They further observed reduced dyspnea and increased SpO2 within 48–96 h after the first infusion in seven patients. Of these seven patients, five were discharged from the ICU within 2–7 days	Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran	Perinatal tissues MSC	2 × 108 cells	3	Intravenous	[188]

Current challenges for MSC-based COVID-19 therapies

Currently, there is a large amount of active clinical research occurring in relation to MSCs for the treatment of various diseases. In particular, the clinical research of MSCs for the treatment of COVID-19 has seen explosive developments. However, in addition to the evaluation of the therapeutic effects of MSCs, more in-depth problems require clarification [193]. The main clinical challenges relating to the use of MSCs to treat COVID-19 are presented in Fig. 4.

Fig. 4.

The main challenges and corresponding strategies of MSC-based therapies in clinical applications. There are three steps for the clinical application of MSCs in COVID-19. The first is the collection of MSCs from different sources, then the isolation, identification, and multiplication of MSCs in vitro, and finally, the infusion of MSCs into COVID-19 patients. The challenges faced in each step and their corresponding strategies to overcome these challenges are summarized

First, thrombosis is common in COVID-19, particularly in critically ill patients [194, 195]. COVID-19-specific coagulopathy is caused by increased levels of fibrinogen, von Willebrand factor (vWF), fibrin degradation product, and d-dimer in the blood [196]. SARS-CoV-2 infection induces an inflammatory process called immuno-thrombosis, which activates the interaction of monocytes and neutrophils with platelets and the coagulation cascade, resulting in the formation of intravascular thrombi in small and large blood vessels [196, 197]. During immuno-thrombosis, neutrophils and monocytes can secrete tissue factors and regulate the extracellular nucleosomes to degrade endogenous anticoagulants, thereby promoting inflammation-induced coagulation activation. When immuno-thrombosis is not controlled, it leads to the unregulated activation of the coagulation cascade, which in turn leads to micro-thrombosis and inflammation, creating a positive-feedback-like cycle, which eventually may develop into thrombosis (thrombotic inflammation) and diffuse intravascular coagulation [198]. Thus, thromboprophylaxis and immuno-thrombosis must be monitored in hospitalized COVID-19 patients in the absence of contraindications. Different MSC products show different levels of high procoagulant tissue factor and may have adverse effects on the immediate blood-mediated inflammatory response (IBMIR). Appropriate strategies for evaluating and controlling blood compatibility and optimizing cell delivery are critical for the development of safer and more effective MSC therapies [199].

Second, we should emphasize that due to the unique nature of the COVID-19 outbreak and the ethical restrictions on treating severe COVID-19 patients, not all clinical trials used a standard design. From the perspective of safety and effectiveness, the clinical use of autologous MSCs is the best method to treat COVID-19. However, the production of a clinically relevant number of MSCs requires a significant amount of time, which is not always the case in the current COVID-19 emergency. A large number of MSCs are urgently needed, and the corresponding quality of MSCs must also be strictly controlled.

Third, there is concern regarding the use of fresh and frozen MSCs due to their different therapeutic roles. Moll et al. found that the difference between using fresh and frozen MSCs was significant [200, 201]. In six published clinical reports, allogeneic sources were used, of which only two studies used freshly cultured BM-MSCs [202, 203] and the other studies used previously cryopreserved BM-MSCs [61, 204], which can play a certain therapeutic effect in terms of curative effect using cryopreserved MSCs. Undoubtedly, fresh MSCs were the best choice. However, due to the COVID-19 outbreak, there is currently an insufficient number of donors available to provide fresh tissue samples. In addition, growth in a short period of time is difficult, and access to cell processing facilities may also be limited. Therefore, when conditions permit, fresh MSCs are the first choice, but in emergency situations, frozen MSCs can be utilized. More studies comparing the differences between fresh and frozen MSCs and interpreting existing preclinical data are required to increase our understanding and provide a higher standard of care.

Fourth, regardless of which part of the human body the MSCs were obtained and isolated from, they must be processed in a facility that follows a good manufacturing practice (GMP) and can ensure that the MSCs meet clinical quality standards. Although the effectiveness of MSCs from different sources in the treatment of COVID-19 has been studied, more optimized treatment strategies for evaluating and controlling hemocompatibility, optimizing cell infusion, and monitoring the real-time dynamics of cells in the body are essential for the development of safer and more effective MSC therapies [199]. In theory, MSCs can be isolated from most tissues of the human body but are very restricted clinically due to the limited availability of the source tissues, the invasiveness of the procedure, and the general conditions of the donor. It is important to select a suitable cell source, evaluate the difficulties in obtaining samples, and consider the possible adverse effects of the procedure. In summary, although MSCs isolated from different tissues show different common characteristics, their biological functions and markers can differ depending on the tissue source. For many countries, especially developing and underdeveloped countries, the availability of such GMP-compliant cell processing facilities and ensuring the provision of clinical-grade MSCs are major challenges [205]. Even within the same organization, each country may have certain differences and heterogeneity in the production processes with different patient groups using MSCs from different sources.

Then, the high cost of MSC products is an ongoing issue that hinders their large-scale application in the treatment of COVID-19 [206]. Unlike conventional therapeutic methods, MSCs can be collected from both autologous and allogeneic organisms. Standard protocols must be followed when collecting MSCs from the various different sources [207]. Highly specialized technical staff, time costs, technical costs, material costs, testing equipment, quality control costs, cell preservation, and cell transportation costs all require strict maintenance and management by specialized personnel. These personalized procedures make stem cell therapy very expensive. Further investigations into how to effectively control these costs must be conducted in future.

Finally, there is a lack of long-term follow-up data on the tolerance and safety of MSC infusions. Meng et al. conducted a study that included 18 patients with moderate to severe COVID-19, nine of whom received UC-MSC infusion therapy [182]. Based on their results, intravenous infusions of UC-MSCs were found to be safe and well tolerated during the one-month follow-up period. Clinical studies have shown that MSCs have a good therapeutic effect, but some studies have reported that allogeneic AD-MSC infusions are ineffective at improving immune recovery or reducing immune activation and inflammation in patients with an immune response [44]. Our study found that a small number of patients still had adverse events greater than grade 3 at the one-month follow-up period after post-menstrual blood-derived MSC transplantation [181]. Although these adverse events are not considered to be a direct effect of the MSC treatment itself, further verification is still required. Moreover, these clinical studies are currently based on a small sample of participants. Therefore, although MSC transplantation is an effective method for treating COVID-19, particularly critically ill patients, further large-scale clinical studies, potential treatment mechanisms, and long-term safety studies are still required.

Prospective directions for MSC-based COVID-19 therapies

It is worth noting that intravenous infusions of convalescent plasma can currently be used treat patients with severe COVID-19 and could easily be combined in future with MSC transplants to inhibit cytokine storms, promote lung injury repair, and the recovery of lung function [208]. It is also important to consider that MSCs derived from different tissue sources have phenotypic heterogeneity and exhibit different differentiation possibilities and the release of different biologically active factors [209]. Thus, selecting source MSCs with specific biological properties will help to enable precision therapies in future [210]. For critically ill elderly patients with COVID-19, ready-made sources of allogeneic cells are the best choice. However, for younger patients who are likely to develop COVID-19, autologous sources, such as AD-MSCs, can be used. Furthermore, autologous menstrual blood MSCs may be a good choice for women. Selecting a suitable source for MSCs is vital for the effective treatment of COVID-19. As MSC sources have different quality criteria and researchers have different clinical grades for MSC products, regulations from authorities and clinical guidelines are necessary [211, 212]. To achieve global consensus, some specialists have already proposed therapeutic guidelines for MSC COVID-19 treatments [213, 214].

Understanding the origin of the global COVID-19 pandemic and public health emergency is an ongoing process. It is clear, however, that we must develop a better understanding of how animal viruses can jump species boundaries and effectively infect humans to help prevent future zoonotic events [215]. Some studies have found that bats and pangolins were the intermediate hosts for SARS-CoV-2 [72, 76–79], while other recent studies have found that pets, including cats and dogs, are also susceptible [81, 82]. Therefore, it is possible that the virus infected humans indirectly via transmission from wild animals to domestic pets. However, these are conjectures. The true origins and the process of how viruses infect specific animals and subsequently pass to humans should be explored from all angles in future.

Due to a lack of studies comparing the efficacy of MSCs and MSC-derived EVs, it is currently unclear which treatment should be used. Current reports of MSC-derived EVs for the treatment of COVID-19 are continuous and effective [216–220]. However, since some studies have verified the importance of direct cell contact to the success of treatment and considering the urgency of treatment, it makes sense to use MSCs directly. Nevertheless, both therapies are likely to be accepted, as evidenced by clinical studies with COVID-19 patients. Based on this evidence, we hypothesize that MSCs in the form of a freeze-dried powder, administered by intravenous transplant (or inhalation, etc.), may be a suitable method for treating COVID-19 in future, particularly critically ill patients. Further analysis of MSCs and MSC-EVs will help to further understand the differences and respective advantages of these treatment methods.

Conclusion

Clinical studies have indicated that MSCs from various sources could be utilized in future treatment methods for patients with COVID-19 (especially critically ill patients). MSCs have already shown potential as adjuvant treatments for COVID-19 in preliminary studies. However, MSC treatments for COVID-19 are currently lacking important long-term safety information and data from large-scale controlled trials, which is required to make conclusive judgments. With the continuous development of new technologies, we have come to understand that combined treatments can be more effective and advantageous, and that we should keep this in mind when considering treatments for COVID-19 in future. Thus, MSC-based treatments combined with other treatment methods could play a powerful role in developing effective strategies to combat COVID-19.

Author contributions

LC wrote the manuscript; JQ, FSK, QZ, LF, YF, YL collected the references and modified the manuscript; CX designed the manuscript and approved the final manuscript for publication.

Funding

This work was supported by the National Natural Science Foundation of China (81900563 and 81802278), the Zhejiang Key Research and Development Program (2020C03125 and 2020C04016), the Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, and the National Key R&D Program of China, Key Technologies Research and Development Program (2017YFA0105701).

Data availability

Please contact the corresponding author for data requests.

Declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Not applicable.